Evidence map›Paper›PMID 38624552›Full record

ReviewThe Egyptian journal of medical human genetics2020

Understanding the genetic determinant of severity in viral diseases: a case of SARS-Cov-2 infection.

Babayemi Olawale Oladejo, Covenant Femi Adeboboye, Tinuola Tokunbo Adebolu

Open access · diamondAbstract readReview
In one paragraph

Review in The Egyptian journal of medical human genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. British journal of biomedical science · 2022
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Babayemi Olawale OladejoDepartment of Microbiology, Federal University of Technology, P.M.B. 704, Akure, Nigeria.ORCID 0000-0002-3284-8781
Covenant Femi AdeboboyeDepartment of Microbiology, Federal University of Technology, P.M.B. 704, Akure, Nigeria.
Tinuola Tokunbo AdeboluDepartment of Microbiology, Federal University of Technology, P.M.B. 704, Akure, Nigeria.
Federal University of Technology · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Numerous research studies have identified specific human gene variants that affect enhanced susceptibility to viral infections. More recently is the current pandemic where the SARS-CoV-2 infection has shown a high degree of person-to-person clinical variability. A wide range of disease severity occurs in the patients' experiences, from asymptomatic cases, mild infections to serious life threatening conditions requiring admission into the intensive care unit (ICU). Main body of the abstract: Although, it is generally reported that age and co-morbidities contribute significantly to the variations in the clinical outcome of the scourge of COVID-19, a hypothetical question of the possibility of genetic involvement in the susceptibility and severity of the disease arose when some unique severe outcomes were seen among young patients with no co-morbidity. The role human genetics play in clinical response to the viral infections is scarcely understood; however, several ongoing researches all around the world are currently focusing on possible genetic factors. This review reports the possible genetic factors that have been widely studied in defining the severity of viral infections using SARS-CoV-2 as a case study. These involve the possible involvements of ACE2, HLA, and TLR genes such as TLR7 and TLR3 in the presentation of a more severe condition. Short conclusion: Understanding these variations could help to inform efforts to identify people at increased risk of infection outbreaks through genetic diagnosis of infections by locating disease genes or mutations that predispose patients to severe infection. This will also suggest specific targets for therapy and prophylaxis.

Indexed as

Angiotensin-converting enzyme 2 (ACE2) geneCoronavirusCOVID-19Human leucocyte antigen (HLA) alleleSARS-CoV-2Toll-like receptor (TLR)

Identifiers

PMID38624552
PMCPMC7773422
OpenAlexW3116961761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.